New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
10:16 EDTGTN, CTSH, IMGN, AXASHigh option volume stocks: IMGN GTN RDA AXAS CTSH
News For IMGN;GTN;AXAS;CTSH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
10:00 EDTIMGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:44 EDTIMGNImmunoGen downgraded to Hold from Buy at Cantor
Cantor Fitzgerald analyst Mara Goldstein downgraded ImmunoGen to Hold citing the recent really in shares. The analyst raised her price target for the stock to $21 from $12.
July 31, 2015
06:36 EDTIMGNImmunoGen: enrollment in expansion cohort for IMGN853 to complete by year end
Subscribe for More Information
06:34 EDTIMGNImmunoGen sees FY16 revenue $70M-$80M, consensus $87.4M
Sees FY16 operating expenses $175M-$180. Sees FY16 net loss to be 120M-$125M. Sees FY16 cash used in operations $100M-$105M. Sees FY16 CapEx $13M-$15M. Sees FY16 cash and marketable securities anticipated to be $165M-$170M.
06:32 EDTIMGNImmunoGen reports Q4 EPS (35c), consensus (35c)
Reports Q4 revenue $12.61M, consensus $15.42.
July 29, 2015
08:29 EDTIMGNImmunoGen price target raised to $24 from $13 at Oppenheimer
Oppenheimer hiked its price target on ImmunoGen as the firm thinks that updates on its '853 drug will better frame the drug's value. The firm believes that several other positive catalysts will propel the stock higher in 2016. It keeps an Outperform rating on the shares.
July 28, 2015
16:41 EDTAXASAbraxas Petroleum reports Q2 production averaged 5,471boepd
Subscribe for More Information
07:10 EDTCTSHCognizant removed as a top pick at Deutsche Bank
Subscribe for More Information
July 23, 2015
11:22 EDTAXASAbraxas Petroleum 'unaware' of reason for recent stock price underperformance
Abraxas Petroleum Corporation commented on recent market conditions. Aside from weakness in the general commodity markets, Abraxas is unaware of any fundamental reason for the company’s recent stock price underperformance. Abraxas notes that the company exited June 30, 2015 $108 million borrowed on the company’s $165 million borrowing base. With an additional nine well completions during the quarter, and only bank deb in the Company’s capital structure, the company is very comfortable with its asset coverage. Additionally, with a $55 million capital program that approximates forecasted cash flow, the company remains comfortable this strong financial positioning should continue through 2015. Moreover, the company reiterates that in outer years, it currently forecasts it can hold production at over 7,000 boepd running a one rig Bakken program, which approximates a $50-$60 million capital program. Abraxas also reiterates the company’s 2015 production guidance of 6,500-7,000 boepd. Abraxas plans to close out the company’s second quarter production and financial results the week of July 27, 2015. In the coming week Abraxas will also have 30 day rates for the company’s four Bakken and two Eagle Ford completions. When these results are available, Abraxas will furnish them to the Street.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use